Chinook Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Chinook Therapeutics

10/11/2022 21:11

* Chinook Therapeutics Inc  KDNY.OQ  reported a quarterly
adjusted
loss of 83 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 63 cents per share.
    * Revenue rose 62,425% to $2.50 million from a year ago;
analysts
expected $100.00 thousand. 
    * Chinook Therapeutics Inc's reported EPS for the quarter
was a
loss of 83 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chinook Therapeutics Inc shares had risen by 11.6% this
quarter and gained 34.6% so far this year.
    * The company reported a quarterly loss of $55.98 million.
    * Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $32.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 09:10 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.63          -0.83          Missed
 Jun. 30 2022      -0.61          -0.61          Met
 Mar. 31 2022      -0.67          -0.54          Beat
 Dec. 31 2021      -0.68          0.14           Beat